SCHEMBL4114790

SCHEMBL4114790

COc1ccc(C(=O)n2c(C(=O)O)cc3cc(OC)ccc32)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ HPGD P15428 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ HSD17B10 Q99714 1/20 0.63
▸ AKR1C3 P42330 6/20 0.61
▸ AKR1C2 P52895 5/20 0.61
▸ TUBB1 Q9H4B7 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ CCR2 P41597 2/20 0.49
▸ PTGS2 P35354 2/20 0.48
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CNR2 P34972 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ HIF1A Q16665 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7321174 0.84 KDM4E (0.68) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL4369004 0.78 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL16746715 0.78 AKR1C3 (0.81) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL3969204 0.77 PARP1 (0.49) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL15684644 0.76 AKR1C3 (0.77) KDM4EAKR1C3AKR1C2TUBB1PTGS2
SCHEMBL11037919 0.76 AKR1C3 (1.00) KDM4EAKR1C3AKR1C2TUBB1PTGS2
SCHEMBL29941900 0.76 AKR1C3 (0.77) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL29481380 0.76 AKR1C3 (1.00) KDM4EAKR1C3AKR1C2TUBB1PTGS2
Acetic Acid SCHEMBL11761270 0.76 AKR1C3 (0.93) KDM4EAKR1C3AKR1C2TUBB1PTGS2
SCHEMBL700814 0.74 KDM4E (0.67) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410130-B2 Synthesis of 8H-3A-aza-cyclopenta [A ]indenes and 5,10-dihydropyrrolo[1,2-B]isoquinolines derivatives and their use as antitumor therapeutic agents ACADEMIA SINICA (TW) 2013-04-02 — — US disclosed
US-20090117125-A1 SYNTHESIS OF 8H-3A-AZA-CYCLOPENTA[A]INDENES AND 5,10-DIHYDROPYRROLO[1,2-B]ISOQUINOLINES DERIVATIVES AND THEIR USE AS ANTITUMOR THERAPEUTIC AGENTS MEMORIAL SLOAN KETTERING CANCER CENTER 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117125-A1 SYNTHESIS OF 8H-3A-AZA-CYCLOPENTA[A]INDENES AND 5,10-DIHYDROPYRROLO[1,2-B]ISOQUINOLINES DERIVATIVES AND THEIR USE AS ANTITUMOR THERAPEUTIC AGENTS TOP2B, TOP2A, TOP1 KDM4E 125/4885ALDH1A1 373/4885HPGD 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback